Jonathan Milner

Jonathan Milner General Information

Description

Dr. Jonathan Milner is a Co-Founder and serves as Chairman at Axol Bioscience. He serves as Board Member at PhoreMost and GeoSpock. He serves as Chairman at Nucler. He served as Board Member at Camallergy. He also serves as a Member of the Advisory Panel at Cambridge Innovation Capital. He is a co-founder of Abcam and is an experienced entrepreneur and investor and is passionate about supporting UK healthcare and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on AIM. He gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath University. From 1992-95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the laboratory of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Kouzarides. He is currently Chairman of Axol Bioscience and Definigen Limited. He serves as non-executive director of Horizon Discovery, Syndicate Room Limited, Repositive Limited, Elpis Biomedical Limited, Shift Biosciences Limited, HealX Limited. He was on the advisory board of Desktop Genetics Ltd. He serves as Board Member and Advisor at LIfT BioSciences.